Rybelsus, the first oral GLP-1 receptor agonist, has been reshaping diabetes management since its approval. Understanding its mechanism of action highlights why timing matters in treatment regimens. The active ingredient, semaglutide, works by mimicking the incretin hormone, which plays a crucial role in glucose metabolism. When you take Rybelsus, it…